Arcera’s sovereign-backed ambition to build a global life sciences bridge

Established by ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, Arcera is redefining what it means to build a global healthcare company from the region. In an industry often shaped by short-term market cycles, Arcera combines the independence of a privately held company with the scale and ambition of a global player, backed by a clear mandate to expand into new markets and strengthen healthcare resilience.

For Rafael Ferrer, senior vice president corporate development, that difference is more than structural. It defines how Arcera approaches growth. Talking to The Pharma Letter, he explains: “We’re not really constrained by the quarterlies. We’re able to really think about longer-term bets in terms of how we build a vision and how we build partnerships.”

In addition to its long-term focus, the group is defined by its breadth of vision. Created in 2024, Arcera integrated Swiss pharmaceutical player Acino, Egyptian manufacturer Amoun and Turkey’s contract manufacturer Birgi Mefar Group under one umbrella.

With more than 2,000 branded medicines, over 6,000 employees and operations in over 60 countries, the group now has a sizable footprint reaching patients in more than 120 markets. Its focus is high-growth markets, where it claims leadership positions in the Middle East, South Africa, Latin America and Ukraine.

Yet, integration of these legacy businesses gives it more than geographic reach. Abu Dhabi is positioning itself as a crossroads for global healthcare investment, aligned with the UAE’s Vision 2030. “Abu Dhabi really offers a very unique pool of human capital, an extremely robust infrastructure, truly supported by investment,” says Mr Ferrer. That base, he argues, allows Arcera to be a life sciences group of genuine global scale to emerge from the Gulf.

At the same time, Arcera has sought to preserve the brands of its constituent businesses. Acino is a well-established name in branded medicines, with deep networks across Latin America, the Middle East, Eurasia and Africa. Amoun is a leading Egyptian manufacturer with strong leadership position in the market. Birgi Mefar is a contract developer and manufacturer with specialized sterile injectable capabilities. Arcera is integrating and strengthening the businesses to accelerate growth and scale while still leveraging the local credibility and market leadership.

Partnerships as a growth engine

With expansion as the goal, partnerships and acquisitions are central. Arcera has been active in licensing deals across its regions, bringing in therapies for ADHD, diabetes, osteoarthritis and rare cancer-related conditions. The firm recently signed an agreement for AriBio’s AR1001 in Alzheimer’s for all its markets, a move that illustrates its intent to diversify into higher-value specialty medicines.

Mr Ferrer emphasizes that the company sees itself as the partner of choice for innovators, aiming to reach patients across high-growth markets. The pitch is straightforward: global biotechs can access Arcera’s regulatory, marketing and on-the-ground commercial infrastructure to distribute products in geographies that are otherwise difficult to penetrate.

“If you’re an innovative biotech in the US, Europe or Asia, we can be the conduit to bring your products across our markets in a wide array of therapeutic areas,” he explains. Priority areas include cardiometabolism, neurosciences, gastroenterology, oncology, immunology, and rare diseases.

That flexibility will enable Arcera to act quickly when an attractive partner emerges, following Mr Ferrer’s formula for a successful alliance, an approach that boils down to “the “three Ts,” namely: “timeliness, transparency and trust.”

Playing the long game

Unlike public firms bound to investor cycles, or private equity-backed groups under pressure for quick returns, Arcera’s mandate is long-term, and the Company has plans to grow into a self-sustained, profitable business with a focus on innovation. Mr Ferrer contrasts his current position with his previous roles in big pharma and private equity-backed ventures. The difference, he suggests, is the ability to invest in relationships and strategic bets that may take years to pay off. This mindset informs the company’s pursuit of opportunities in the USA, Europe and elsewhere. “To be a global life sciences company, you need to enter new markets, in order to serve more patients and prescribers,” he says. That means acquisition opportunities are firmly on the table, with Arcera scanning for assets that could accelerate its reach in developed markets.

While that ambition sounds familiar, the ability to execute without the burden of quarterly earnings sets the company apart. Mr Ferrer believes this patience gives Arcera a distinctive advantage. “The goal is we’re building something for the future,” he explains. “Our goal really is to build a global leader in both innovative and sustainable healthcare.”

Bridging emerging and developed markets

The dual identity, ADQ-backed, high growth-markets leader with global aspirations, defines its uniqueness. The group operates in Brazil, Mexico, UAE, Saudi Arabia, Ukraine and South Africa, and its leaders aim to transform this reach into a bridge connecting global innovation ecosystems.

China is one example. With a rising profile in oncology and neuroscience, its biotech sector is producing drugs that often struggle to globalize. Arcera sees itself as a potential bridge for innovation, helping bring therapies from Asia to other markets. “We are actively looking at partnerships with Chinese innovators to bring those products from China to the rest of the world,” he notes.

The same principle applies in reverse. For smaller US or European biotechs without the infrastructure to commercialize in Latin America or the Middle East, Arcera offers a route to patients and prescribers. By positioning itself as a connector, the company aims to capture value in both directions.

Being headquartered in Abu Dhabi confers symbolic and practical advantages. The UAE is investing heavily in healthcare as part of its diversification away from hydrocarbons. That means state support for infrastructure and a policy environment favorable to life sciences. The Gulf location also offers logistical reach into Europe, Africa and Asia.

Looking ahead

For all its scale, Arcera remains young. Incorporated less than two years ago, it still has a long journey ahead. The ambition is clear: to build a global life sciences company spanning general medicines, specialty pharmaceuticals, and eventually digital health, medtech and other life science segments.

Mr Ferrer acknowledges that this will require more than organic growth. “A key pillar is our acquisition strategy, focusing on how we grow into some of the markets like the US and Europe where we’re not present,” he says. The group is scouting for companies in attractive markets with strong demographics, high unmet need and room for long-term expansion.

The foundation, Mr Ferrer insists, is already in place. “We are a very unique bridge to truly be global in our approach to help people live longer and healthier lives,” he says. “Not just the top markets, but truly to be a conduit and doing all of this through a patient-first lens.”

If Arcera can deliver on that promise, it may emerge as one of the most significant new entrants in global life sciences.